Welcome to the Zenith Epigenetics Hub On AGORACOM

Zenith's Lead Pan Selective BET Inhibitor ZEN-3694 is Currently Being Evaluated in Phase 1 Prostate Cancer Clinical Trials

Free
Message: Zenith share issue

would love to see a major deal with a BP but we have never had one to this point,  It would hugely legitimize the science of Zenith and RVX and would be a good catalyst for share movement for RVX   (IMO)  

Share
New Message
Please login to post a reply